Journal Article

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Yamanaka, Kazunori, Yamashita, Riu, Oki, Eiji, Yamamoto, Kouji, Kato, Takeshi, Tsuchihara, Katsuya, Takashima, Atsuo, Ochiai, Atsushi, Yokota, Mitsuru, Akagi, Kiwamu, Hihara, Masamitsu, Shitara, Kohei, Komatsu, Yoshito, Miwa, Keisuke, Soeda, Junpei, Yasui, Hirofumi, Makiyama, Akitaka, Ojima, Hitoshi, Naitoh, Takeshi, Uetake, Hiroyuki, Yamazaki, Kentaro, Sato, Takeo, Akazawa, Naoya, Yoshino, Takayuki, Shiozawa, Manabu, Misumi, Toshihiro, Mori, Ikuo, Muro, Kei, Ohori, Hisatsugu, Watanabe, Jun, Yuasa, Yasuhiro

2024

Overview

Certain genetic alterations and right-sided primary tumor location are associated with resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer (mCRC). The phase 3 PARADIGM trial ( n  = 802) demonstrated longer overall survival with first-line anti-EGFR (panitumumab) versus antivascular endothelial growth factor (bevacizumab) plus modified FOLFOX6 in patients with RAS wild-type mCRC with left-sided primary tumors. This prespecified exploratory biomarker analysis of PARADIGM ( n  = 733) evaluated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes, focusing on a broad panel of gene alterations associated with resistance to EGFR inhibition, including KRAS , NRAS, PTEN and extracellular domain EGFR mutations, HER2 and MET amplifications, and ALK , RET and NTRK1 fusions. Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62–0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83–1.53), regardless of tumor sidedness. Negative hyperselection using ctDNA may guide optimal treatment selection in patients with mCRC. ClinicalTrials.gov registrations: NCT02394834 and NCT02394795 . In an exploratory preplanned biomarker analysis of the phase 3 PARADIGM trial, a lack of resistance gene alterations in baseline circulating tumor DNA (negative hyperselection) was associated with prolonged overall survival after first-line panitumumab with chemotherapy in patients with RAS wild-type metastatic colorectal cancer.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/67/68 / 692/53/2422 / Antibodies, Monoclonal - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Bevacizumab / Bevacizumab - therapeutic use / Biomarkers / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Chemotherapy / Colonic Neoplasms - drug therapy / Colorectal cancer / Colorectal Neoplasms - drug therapy / Colorectal Neoplasms - genetics / Colorectal Neoplasms - pathology / Deoxyribonucleic acid / DNA / Epidermal growth factor receptors / ErbB Receptors - genetics / ErbB-2 protein / Growth factors / Humans / Infectious Diseases / Metabolic Diseases / Metastases / Metastasis / Molecular Medicine / Monoclonal antibodies / Neurosciences / Panitumumab - therapeutic use / Proto-Oncogene Proteins p21(ras) / PTEN protein / Rectal Neoplasms - drug therapy / Survival / Targeted cancer therapy / Tumors